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ABSTRACT
Patients with Paget’s bone disease (PDB) have an increased risk of developing giant cell tumor (GCT). This study was performed to
evaluate the clinical characteristics and evolution of GCT complicating PDB and to compare these clinical characteristics to those
observed in two large PDB cohorts, the PDB Italian Registry and the United Kingdom’s Multi‐Centre Randomised Controlled Trial of
Symptomatic Versus Intensive Bisphosphonate Therapy for Paget’s Disease (PRISM) study. A systematic literature review identiﬁed
117 cases of PDB complicated by GCT (PDB‐GCT), which involved the skeletal sites affected by PDB (110 patients) or the extraskeletal
tissues adjacent to affected bones (7 patients). In contrast to what previously reported for GCT patients without GCT patients (83.2%)
were white and one‐fourth of them (24.8%) hadmultifocal GCTs. Compared to PDB patients without GCT, PDB‐GCT patients showed a
higher male/female ratio (2.1 versus 1.2) and more severe disease (age at PDB onset 52.1 12.1 versus 63.3 10.6 years; number of
affected sites 6.1 2.9 versus 2.34 1.6; prevalence of polyostotic PDB 93.3% versus 60.6%). The mortality rate of PDB‐GCT patients
was higher than those occurring in GCT patients without PDB (about 50% versus 0% to 5% at 5 years) or in PDB patients without GCT
(log rank¼ 29.002). Moreover, up to 98% of PDB‐GCT cases had elevated total alkaline phosphatase levels at neoplasm diagnosis,
suggestive of active PDB. Importantly, PDB‐GCT patients from Southern Italy (45.6% of all GCT patients) showed a higher prevalence of
multifocal GCT (51.7%) and of positive familial history for PDB (70.8%) and GCT (65.0%). Finally, indirect evidence suggests a decline in
the incidence of GCT in PDB patients. The occurrence of GCT in PDB patients is associated with severe disease and reduced life
expectancy of affected patients. The increased prevalence of familial diseases in PDB‐GCT patients from Southern Italy suggests a
founder effect. The observed changes over time in the incidence of GCT in PDB patients could be related to improved clinical
management and/or living conditions of patients. © 2014 American Society for Bone and Mineral Research.
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Introduction
Paget’s bone disease (PDB; OMIM# 602080) is a focal disorderwith a strong genetic component characterized by increased
and disorganized bone remodeling, bone expansion, and
abnormal bone structure.(1,2) Among the several complications
of this disorder, patients with PDB are at greatly increased risk of
developing primary bone neoplasms as compared to controls.
These mainly include osteosarcoma and, less frequently, giant
cell tumor (GCT).(3–9) Accounting for 6% of all primary bone
neoplasms, GCTs are composed of multiple cell types.(10) The
name is based on the numerous multinucleated giant cells
found within the tumor, which are responsible for the extensive
local osteolysis.(10,11) However, the neoplastic components of
GCT are the spindle‐like stromal cells, which promote giant cell
formation and largely direct the pathogenesis of the tu-
mor.(10,12) In contrast with osteosarcomas, although locally
aggressive, GCTs rarely metastasize (2% to 6% of cases).(13) In a
recent study in a large pedigree with GCTs complicating PDB
(PDB‐GCT patients), we demonstrated an increased disease
severity associated with impaired response to antiresorptive
treatment and an increased prevalence of cardiovascular
complications.(14) In order to conﬁrm these ﬁndings and to
enhance knowledge about this PDB complication, we per-
formed a systematic review of all reported GCT cases in PDB
patients and we compared disease characteristics of these
patients with those observed in two large cohorts of unrelated
PDB subjects.
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Patients and Methods
Data sources and searches
We conducted a systematic review to identify cases of GCT
occurring in PDB patients (PROSPERO database registration
number: CRD42014007030). The systematic search was per-
formed according to Preferred Reporting Items for Systematic
Reviews and Meta‐Analyses (PRISMA) criteria (Supporting Fig. 1,
Supporting Table 1). A total of 102 studies were included in the
ﬁnal synthesis (Supporting Table 2).
Patient populations
Clinical information from PDB‐GCT cases were compared with
those reported in two large cohorts of unrelated PDB patients
from Italy and the UK, namely the Italian Registry of PDB (n¼ 718)
and the United Kingdom’s Multi‐Centre Randomised Controlled
Trial of Symptomatic Versus Intensive Bisphosphonate Therapy
for Paget’s Disease (PRISM) study (n¼ 774) (Table 1).
Statistical analysis
At univariate analyses, statistical comparisons were based on the
Student’s t test with Bonferroni correction when requested, for
continuous variables, and on the x2 test for dichotomous
variables. Logistic regression models, based on the results of
univariate analyses, were generated to evaluate the possible
statistical interference between the given variables. Moreover,
linear regression analysis and Pearson’s correlation were
performed in order to explore the degree of intervariable
associations for interval and nominal variables, respectively.
Kaplan‐Meier survival curves were also obtained. Quantitative
data were expressed as mean SD. Statistical analysis was
performed using a SPSS statistics package, version 11.5 (SPSS,
Chicago, IL, USA) and Statistica 5  1 (Statsoft, Tulsa, OK, USA). All
statistical tests were two‐tailed. A p value <0.05 was considered
statistically signiﬁcant.
Results
Characteristics of GCT in PDB
The systematic review identiﬁed 117 cases of PDB complicated
by GCT (ie, PDB‐GCT patients). In 110 patients (94%) GCT
occurred in bones affected by PDB (skeletal GCT), whereas in 7
cases (6%) the neoplasm occurred in extraskeletal tissues
(extraskeletal GCT), adjacent to bones affected by PDB
(Supporting Table 3). PDB‐GCT patients showed a higher male/
female ratio, an increased prevalence of polyostotic and familial
PDB, and an earlier age at onset of PDB compared to PDB
patients without GCT from the Italian Registry and the PRISM
study (Table 1). The GCT was single in 88 cases and multifocal
(synchronous or asynchronous) in 29 cases (Table 2). Twenty‐
seven of the 110 patients with skeletal GCT (24.5%) had
multifocal GCT; among them, 18 had two GCTs and 9 had three
or more GCTs. Up to 27 GCTs were described on more than one
occasion in the same PDB patient in different reports. The mean
age at onset of GCT was 62.5 11.7 years. PDB patients with
multifocal GCT showed amean age at onset of the ﬁrst neoplasm
signiﬁcantly lower compared to those with single GCT (Table 2).
The large majority of PDB‐GCT patients in whom race/ethnicity
was reported (65/79; 82.3%) were white (most of them of
European ancestry), 8 (10.1%) were black, and 6 (7.6%) were
Asian. No differences were observed in the prevalence of gender,
single or multifocal GCT, and skeletal or extraskeletal GCT
between racial/ethnic groups. Conversely, an earlier age at onset
of GCT was observed in Asian PDB patients compared to white
and black patients (Asian versus white versus black patients¼
48.8 9.3 versus 62.4 10.2 versus 62.2 13.7 years; p¼ 0.011).
Fifteen out of 43 (35%) PDB‐GCT patients with available
information had at least one ﬁrst‐degree relative affected by
both diseases; in those 15 cases there was a higher prevalence of
multifocal GCTs compared to patients without a familial history
for PDB and GCT (9/15 versus 5/28). The mean age at onset of
GCT in patients with familial PDB and GCT was lower but not
signiﬁcantly different compared to those observed in patients
without familial PDB andGCT (56.8 6.1 versus 62.4 14.1 years;
p¼ 0.08).
Details of the sites affected by skeletal GCT are also shown in
Table 2. GCT involvement of the axial skeleton was observed in
78 cases (75%). Interestingly, PDB patients with multiple skeletal
GCT showed a preferential localization of neoplasms in the spine.
Histological grading, according to criteria proposed by Jaffe,(15)
was available in 101 cases. Overall, GCT lesions of grade 1, 2, and
3 were observed in 25 (24.7%), 52 (51.5%), and 24 (23.8%)
patients, respectively. Histological specimens of 13 PDB‐GCT
cases since 1981 were also examined to evaluate the presence
of intracellular viral‐like inclusions, which were documented in
11 (84.6%) cases.
Table 1. Clinical Characteristics of PDB Patients With or Without GCT
Overall PDB‐GCT White PDB‐GCT Italian PDB Registry PRISM Study (UK)
Patients, n 117 65 718 765
Gender (male versus female), % 67.6 versus 32.4a 66.2 versus 33.8a 57.0 versus 43.0 53.2 versus 46.8
Polyostotic PDB, % 93.3b 90.8b 58.9 62.3
Affected PDB sites, n 6.1 2.9c 6.6 2.9c 2.5 1.9 2.2 1.2
Positive family history of PDB, % 58.5d 62.9e 32.1 12.7
Age of PDB onset, years 52.1 12.1f 52.4 11.2g 59.3 11.9 67.0 9.8
PDB¼ Paget’s disease of bone; GCT¼giant cell tumor.
aData available in 111 PDB‐GCT patients; p¼ 0.038 versus Italian PDB patients and p¼ 0.006 versus PRISM PDB patients.
bData available in 74 PDB‐GCT patients; p< 0.0009 versus Italian PDB patients and versus PRISM PDB patients.
cData available in 74 PDB‐GCT patients; p¼ 0.001 versus Italian PDB patients and p< 0.0009 versus PRISM PDB patients.
dData available in 41 PDB‐GCT patients; p¼ 0.001 versus Italian PDB patients and p< 0.0009 versus PRISM PDB patients.
ep< 0.0009 versus PRISM PDB patients and versus Italian PDB patients.
fData available in 92 PDB‐GCT patients; p¼ 0.031 versus Italian PDB patients and p< 0.0009 versus PRISM PDB patients.
gp¼ 0.038 versus Italian PDB patients and p¼ 0.001 versus PRISM PDB patients.
258 RENDINA ET AL. Journal of Bone and Mineral Research
Characteristics of PDB in PDB‐GCT patients
Data regarding the extent of PDB were available in 104 PDB‐GCT
patients. Themean number of skeletal sites affected by PDB in the
97 PDB‐GCT patients with polyostotic disease was 6.1 2.9 sites
(range, 2 to 14 sites), and there were no major differences
between cases with single or multifocal GCT (Table 2). The axial
skeleton and the symmetrical bones were involved in at least 87
(89.7%) and 66 (68.0%) of polyostotic PDB cases, respectively.
Among the 7 patients with monostotic PDB, the skull and the
mandible were affected in 2 patients, whereas the femur, tibia,
and pelvis were described in 1 patient each. The mean age at
onset of PDB did not differ in relation to gender, family history for
PDB, or between extraskeletal or skeletal GCTs. Conversely, a
trend for an earlier age of onset of PDBwas observed inmultifocal
versus single GCT cases (48.2 10.4 versus 53.3 12.4 years,
respectively; p¼ 0.06). Moreover, the age at onset of PDB was
signiﬁcantly lower in Asian patients compared to white and black
patients (Asian versus white versus black patients: 38.6 12.7
versus 52.4 11.2 versus 52.0 15.7 years; p¼ 0.036). Informa-
tion concerning the time frame between the age at onset of PDB
and the occurrence of GCT was available in 91 patients; in 21
patients (23.1%) the diagnosis of PDB and GCT were made at the
same time, whereas in the remaining 70 cases (76.9%) the
diagnosis of PDB preceded the occurrence of GCT by 12.5 8.9
years (range, 1 to 39 years). Interestingly, in these latter patients a
direct relationship was observed between the ages at onset of
PDB and GCT (r¼ 0.703, p¼ 0.001; Supporting Fig. 2). The time
frame between the diagnosis of PDB and CGTwas similar in those
with single or multifocal GCT (Table 2).
Overall, 24 of 41 PDB‐GCT cases with available information
(58.5%) had at least one ﬁrst‐degree relative affected by PDB. In
patients with familial PDB, the age at onset of PDB, the number of
skeletal sites, the age at onset of GCT, and the prevalence of
single and multifocal GCT were not signiﬁcantly different
compared to GCT cases without familial PDB. Analyzing the
decade at onset of GCT complicating PDB, a progressive decrease
is evident in the percentage of white PDB‐GCT cases (either
Italian or other non‐Italian whites) diagnosed during the last
40 years, with only few cases diagnosed after 1990. An opposite
trend was observed with respect to the decade at onset of PDB
cases without GCT from the Italian Registry and the PRISM study
cohort (Fig. 1, Supporting Fig. 3). This indirectly suggests a
decrease in the prevalence of GCT with age in PDB patients.
Clinical signs and course of GCT
Clinical signs of GCT
The clinical signs and symptoms at the onset of GCT were
available for 99 PDB‐GCT patients. Themost frequent clinical sign
associated with GCT occurrence was the deformity of bones or
Table 2. Clinical Characteristics of PDB‐GCT Patients With Single or Multifocal GCT
Single GCT Multifocal GCT Total
Patients, n (%) 88 (76.2) 29 (24.8) 117
Skeletal:extraskeletal GCT, n 83:5 27:2 110:7
Gender (male:female), n 56:27 19:9 75:36
Age at onset of GCT, years (mean SD) 64.2 12.2 57.4 8.6a 62.5 11.7
Ethnicity (white:black:Asian), n 47:7:3 18:1:3 65:8:6
Family history of PDB‐GCT (yes:no), n 6:23 9:5b 15:28
ALP serum levels at GCT onset, %b 775 632 1020 667 834 644
GCT involving axial skeleton, n 55 23 78
GCT involving skull and mandible 43 12 55
GCT involving pelvis 12 7 19
GCT involving spine 8 10d 18
GCT involving symmetrical bones, n 16 10 26
Age at onset of PDB, years (mean SD) 53.5 12.4 48.2 10.4 52.1 12.1
Time between PDB and GCT diagnoses, years (mean SD) 12.9 8.7 11.5 9.7 12.5 8.9
Family history of PDB (yes:no), n 13:5 11:12 24:17
Skeletal sites involved by PDB, n (mean SD) 5.9 3.1 6.3 25 6.1
Values were determined from PDB‐GCT patients with available information for each characteristic.
ALP¼ alkaline phosphatase; PDB¼Paget’s disease of bone; GCT¼giant cell tumor; PDB‐GCT¼ PDB patients with GCT.
aSigniﬁcantly different compared to PDB patients with single GCT, p¼ 0.009.
bSigniﬁcantly different compared to PDB patients with single GCT, p¼ 0.008.
cThe mean levels of ALP at the diagnosis of GCT are expressed as percentages compared to the maximum laboratory reference range.
dSigniﬁcantly different compared to PDB patients with single GCT, p¼ 0.003.
Fig. 1. Changes over time in the prevalence of GCT occurring in white
(Italian and other non‐Italian) patients with PDB and of PDB diagnosis in
white PDB patients (without personal and familial history of GCT) from
the Italian PDB Registry and the PRISM study cohort. GCT¼giant cell
tumor; PDB¼ Paget’s disease of bone.
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extraskeletal tissues involved by the neoplasm(s). This sign was
observed in 72 PDB‐GCT patients (72.7%), of whom 69 had
skeletal GCT: 49 of 54 patients with GCT of the skull and the
mandible (90.7%); 6 of 10 patients with GCT of the long bones
(60.0%); 10 of 19 patients with GCT of the pelvis (52.6%); and in 4
of 11 PDB‐GCT patients with GCT of the spine (36.4%). While the
count of affected skeletal sites may overlap, the number of GCT
cases with deformity was 72, 69 with bone deformity and 3 with
deformity at extraskeletal sites (69þ3¼72). The second most
frequent clinical feature of GCT was pain, which was referred by
50 patients (50.5%, including 4 with extraskeletal GCT). This
symptom was reported by 75% of patients with GCT of the axial
skeleton. In this setting, pain was linked to physical compression
of neighboring nerves rather than to bone pain. Bleeding was
observed in 10 GCT cases (owing to neoplastic involvement of
the splanchnocranium in 9 cases, and to bladder involvement of
a pelvic GCT in 1 case). Conversely, in the 4 PDB‐GCT cases with
GCT involving symmetrical bones, the clinical diagnosis of GCT
was related to the occurrence of a fracture. Serum levels of total
alkaline phosphatase (ALP) at the onset of GCT were reported in
71 patients. Only 1 patient showed ALP levels within the normal
range, whereas the remaining 70 patients (98.6%) showed
elevated ALP levels. The mean levels of ALP at the diagnosis of
GCT, expressed as percentages compared to the maximum
laboratory reference range, were not signiﬁcantly different
between PDB patients with single or multifocal GCT (Table 2).
Management and clinical course of GCT
Data regarding the treatment of GCT are summarized in
Supporting Table 4. The therapeutic approach to GCT was
inﬂuenced by: (1) the decade at onset of neoplasm (medical
therapy was considered a viable therapeutic alternative after the
1970s); (2) the GCT histological grade (surgical therapy alone or in
combinationwas preferred in GCT grades 1 [20/23] and 2 [35/44],
whereas radiotherapy alone or in combination was preferred in
GCT grade 3 [13/21]); (3) the clinical signs and symptoms at the
onset of GCT (those with the compression of neighboring
structures [13/20] and all cases with a bone fracture were
preferentially managed with a surgical approach alone or in
combination); (4) the characteristics of GCT (multiple GCT [17/26]
and extraskeletal GCT [4/5] were preferentially treated by surgery
alone or in combination); and (5) the skeletal site affected by
GCT (GCT involving the skull [40/52], the spine [10/14], and
symmetrical long bones [10/14] were preferentially treated by
surgery alone or in combination; GCT involving the pelvis [10/15]
was treated preferentially by radiotherapy alone or in combina-
tion). Information regarding the clinical course of GCT was
available in 94 patients. The local recurrence of GCTwas reported
in 26 cases and occurred between 1 and 36 years, with a mean
lapse of time of 7.9 10.7 years. No signiﬁcant differences were
found between patients with or without local recurrence of GCT
with respect to the age at onset of GCT, the percentage ALP
levels at the onset of GCT, the number of skeletal sites affected by
PDB, and the prevalence of familial or sporadic PDB (Supporting
Table 5).
At the end of the observation time, 36 PDB‐GCT patients were
dead (mean age at death 67.9 11.2 years). The clinical
characteristics of PDB‐GCT patients with a fatal outcome,
compared with those who were alive at the end of the
observation time are reported in Table 3; the survival curve
from GCT diagnosis is shown in Fig. 2A. Of interest, the PDB‐GCT
patients who died at the end of the observation time were older,
showed higher ALP levels, and had a higher prevalence of
histological grade 3 GCT at onset of GCT compared to those still
alive. A Cox regression analysis conﬁrmed that age, ALP levels,
and histological grade at GCT onset signiﬁcantly predict the
prognosis with regard to survival of PDB‐GCT patients. Moreover,
PDB‐GCT patients showed a survival curve from PDB diagnosis
signiﬁcantly different compared to PDB patients without GCT
(log rank¼ 29.002; p¼ 0.001; Fig. 2B). The causes of death that
were reported for these GCT cases are summarized in Supporting
Table 6. Of interest, at least 21 PDB‐GCT patients reported the
occurrence of cardiovascular disorders. A positive family history
for PDB and/or GCT was evidenced in at least 8 of these 21
patients andmost of these familial cases were from Campania, in
Southern Italy.
Characteristics in PDB‐GCT cases of Italian descent
An increased prevalence of subjects form Italy or with Italian
ancestors was observed in PDB‐GCT patients described to date.
At least 36 of 79 PDB‐GCT patients of known nationality (45.6%,
23 males and 13 females) were Italian or with Italian ancestors;
among these 36 patients, 29 (18 males and 11 females) were
fromAvellino or neighboring cities of Naples and Foggia. The age
at onset of GCT in these Italian patients was no different
compared to the other white patients or to the other racial/
Table 3. Clinical Characteristics of PDB‐GCT Patients Dead or
Alive at the End of Observation Time
Dead Alive Total
Patients, n (%) 36 (38.3) 58 (41.7) 94
Observation time, years 3.9 5.5 4.1 3.4 4.0 4.4
Single: multifocal GCT, n 27:9 41:17 68:26
Recurrent:nonrecurrent
GCT, n
6:23 20:35 26:58
Skeletal:extraskeletal
GCT, n
35:1 50:5 85:6
Gender (male:female), n 22:13 36:17 58:30
Age at onset of GCT,
years
64.3 11.6a 59.7 9.8 61.5 11.5
ALP serum levels
at GCT onset, %b
1248 790c 652 528 841 683
Histological grade
(1:2:3), n
5:12:17d 15:31:6 20:43:23
Family history of
PDB‐GCT (yes:no), n
5:9 7:17 12:26
Age at onset of PDB,
years
51.6 12.6 51.5 11.2 51.5 11.6
Long bones involved
by GCT, n
5 8 13
Axial skeleton involved
by GCT, n
6 27 33
Family history of PDB
(yes:no), n
7:5 12:12 19:17
Skeletal sites involved by
PDB, n (mean SD)
6.5 3.7 6.2 2.7 6.3 3.1
ALP¼ alkaline phosphatase; PDB¼ Paget’s disease of bone; GCT¼
giant cell tumor.
ap¼ 0.021.
bThe mean levels of ALP at the diagnosis of GCT are expressed as
percentages compared to the maximum laboratory reference range.
cp¼ 0.003.
dp¼ 0.01.
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ethnic groups. However, at least 15 PDB patients with multifocal
GCT (51.7%, 8 males and 7 females) were Italian and 13 of them
(7males and 6 females) were from Avellino or neighboring cities.
Thus, the prevalence of multifocal GCT was highest in patients
from that Italian area. Moreover, the largemajority of familial PDB
cases with GCT were Italian (21/24, 87.5%; p¼ 0.009), and all
these familial Italian cases were from Avellino and neighboring
cities. Comparing the clinical characteristics of PDB‐GCT cases
from Avellino and neighboring cities to those observed in 236
PDB patients (without familial or personal history of GCT) from
that same geographical area, we observed that PDB‐GCT patients
had a lower age at onset of PDB, a higher number of affected
skeletal sites, an increased prevalence of familial PDB, and a
lower prevalence of PDB involvement of the appendicular
skeleton (Table 4).
Discussion
In this study we have for the ﬁrst time conducted a systematic
review of the clinical characteristics and the evolution of GCT
occurring in PDB. Our analysis indicates that this neoplasm
involves skeletal sites affected by PDB or extraskeletal tissues
adjacent to them. Moreover, GCT occurring in PDB patients
shows several peculiar characteristics compared to GCT occur-
ring in absence of PDB (Table 5). In fact, GCT unrelated to PDB is
usually a neoplasm growing eccentrically in the epi‐metaphysis
of long bones and in nearly 50% of cases affects the knee.(16–18)
Conversely, in PDB patients, GCT preferentially involves the axial
skeleton and in particular the skull and facial bones.(19)
Furthermore, GCT unrelated to PDB occurs preferentially in
females, with a male/female ratio of 1/1.5,(16) whereas 75% of
PDB‐GCT patients were males. Although up 25% of PDB‐GCT
Fig. 2. (A) Survival curve of patients with PDB complicated by GCT from
time of GCT diagnosis. (B) Survival curves of PDB patients with and
without GCT from time of PDB diagnosis. GCT¼giant cell tumor;
PDB¼ Paget’s disease of bone.
Table 4. Clinical Characteristics of PDB Patients With or Without
GCT From Avellino and Neighboring Cities
PDB‐GCTa
Italian PDB Registry
(Campania cohort)b
Patients, n 29 236
Gender (male versus
female), %
62.1 versus 37.9 58.2 versus 41.8
Polyostotic PDB, % 93.3 72.8
Affected PDB sites, n 6.4 2.6c 2.8 2.0
Positive family history
of PDB, %
70.8d 20.8
Age of PDB onset, years 50.1 7.4e 58.9 6.1
Involvement of
appendicular
skeleton, %
20.8d 62.7
Involvement of axial
skeleton, %
91.7 82.6
Age of GCT onset, years 57.6 5.9 –
Positive family history
of GCT, %
65.0 –
GCT type (single versus
multifocal), %
56 versus 44 –
PDB¼ Paget’s disease of bone; GCT¼giant cell tumor.
aPDB‐GCT cases from Avellino and neighboring cities.
bPDB patients from Avellino and neighboring cities, selected from the
Italian PDB Registry, without personal and/or familial history of GCT.
cSigniﬁcantly different compared to PDB patients from Campania
without GCT, p¼ 0.002.
dSigniﬁcantly different compared to PDB patients from Campania
without GCT, p< 0.0009.
eSigniﬁcantly different compared to PDB patients from Campania
without GCT, p¼ 0.011.
Table 5. Comparison Between GCTs Occurring in Non‐PDB and
PDB Patients
Non‐PDB GCT PDB‐GCT
Gender female > male male > female
Preferential race/
ethnicity
Asian White
Age of onset, years 20–40 >40
Preferentially affected
skeletal sites
Appendicular bone Axial bone
Multifocal GCT, % <1 25
5‐Year survival rate, % 96–100 <50
GCT¼giant cell tumor; PDB¼ Paget’s disease of bone.
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patients developedmultiple neoplasm, multifocal GCT unrelated
to PDB is a very rare entity that occurs in less than 1% of
cases.(16,20,21) Also, the ethnicity and the age at onset are
remarkably different: GCT unrelated to PDB is more common in
China and India, where it constitutes approximately 20% of all
bone tumors(16); PDB‐related GCT occurs preferentially in white
subjects of European ancestry. In patients without PDB, GCT
occurs in young adults, most often between 20 and 40 years of
age,(16–18,22) whereas pagetic GCT generally occurs after the
fourth decade of life. Of interest, PDB‐GCT patients had generally
elevated serum ALP levels at GCT onset even though many had
previously received pharmacological treatment for PDB, whereas
in adult patients with GCT alone (without PDB) ALP levels where
not different compared to controls.(23) This observation suggests
that GCT generally complicates a longstanding, active, and
polyostotic PDB and is consistent with our previous remarks.(14)
One cannot, however, exclude that high ALP levels are caused by
GCT directly eroding bone. Importantly, the analysis of the
cumulative survival curve indicates that about 80% of PDB
patients died within 10 years from the GCT clinical occurrence
and 50% within 5 years. This 5‐year survival rate is signiﬁcantly
lower than that described for nonmalignant GCT occurring in the
absence of PDB (from 96% to 100%).(16) Moreover, when the time
of PDB diagnosis was considered, a consistent increase in
mortality was observed in PDB‐GCT cases compared to PDB cases
without GCT degeneration. The older age, higher ALP levels at
onset of GCT, and the GCT histological grading were the factors
that signiﬁcantly and independently inﬂuenced the survival of
PDB‐GCT patients. Death from cardiovascular events was also
common, particularly in familial cases and in patients whose
ancestors were from the Italian region of Campania, in keeping
with our previous observations.(14) Osteosarcoma is another rare
but deadly neoplastic complication of PDB. Indeed, some clinical
characteristics of GCT and osteosarcoma complicating PDB are
similar, such as the skeletal localization and the preferential
occurrence in males after the fourth decade of age.(6–9)
Nevertheless, contrary to GCT, multifocal osteosarcomas were
rarely described in PDB patients. Interestingly, even though the
occurrence of osteosarcomas was described in 3 of 33 (9.1%) and
2 of 70 (2.8%) patients with familial PDB in two separate
studies,(24,25) the presence of osteosarcoma in multiple affected
members of the same family was reported only in 2 Italian
siblings from Campania with long‐standing and polyostotic
PDB.(25)
Available data also demonstrate a signiﬁcant prevalence of
familial GCT complicating PDB in Southern Italy (Campania
region and neighboring areas). This geographical area is
historically a unique macroregion(26) and is characterized by
an increased clinical severity of PDB in both sporadic and familial
patients.(27,28) Consistent with this observation, the PDB‐GCT
patients from Campania and neighboring areas showed a more
severe clinical phenotype in terms of age at onset of PDB,
number of skeletal sites affected by PDB, ALP serum levels at PDB
diagnosis, and prevalence of familial PDB disease, compared to
those observed in the two cohorts of PDB cases from Italy and the
United Kingdom and even in the subgroup of PDB patients from
the same geographic area without personal and familial history
of GCT. In particular, a consistent proportion of GCTs occurring in
this Italian region had a positive family history and was more
likely to be multifocal with compared to GCT occurring in other
white patients from different countries or in other racial/ethnic
groups. Thus, at least in these familial cases from Italy, the
pathogenesis of GCT could be related to both genetic and
environmental factors. Indeed, the GCT degeneration also occurs
in PDB patients with ancestors in Southern Italy but who were
born and live in different continents (ie, North and South
America). This phenomenon could be justiﬁed by a founder
effect with genetic drift or selection.(29) Current evidence
suggests that PDB is caused by a combination of rare alleles of
large effect size that cause autosomal dominant inheritance of
the disease andmore common alleles of smaller effect size.(30–32)
Importantly, all PDB patients with GCT and their ﬁrst‐degree
relatives so far examined were negative for the presence of
SQSTM1 mutations.(14,28) Moreover, a recent genomewide
linkage analysis identiﬁed six possible candidate regions on
chromosomes 1, 5, 6, 8, 10, and 20.(14) On the other hand, the
analysis of the changes over time in the prevalence of GCT in PDB
patients from Campania suggests a decrease in the prevalence of
this complication not related to a parallel decrease in the
prevalence of PDB diagnosis. A similar conclusion was also
reached after analysis of the age of diagnosis of other white GCT‐
PDB patients compared with either the Italian Registry or the
PRISM study cohorts of PDB patients without GCT (no GCT cases
were reported in these populations). One can argue that the
improved environmental conditions in most geographical areas
and the recent progress in the pharmacological management of
PDB (with the introduction of more potent intravenous bi-
sphosphonate regimens) could have reduced the occurrence of
this complication, as has also been reported for osteosarcoma
complicating PDB.(5)
In conclusion, our analysis provided novel information
concerning the characteristics and the clinical course of GCT
complicating PDB that can be relevant in clinical practice for both
the prevention and the management of this rare but serious
complication. Additional studies are needed to dissect the
genetic defects associated with the occurrence of GCT in
SQSTM1‐negative pedigrees.
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